Yuhan Corporation
Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 000100.KS | 000220.KS | 016580.KS | 023910.KQ | 003520.KS | 600521.SS | |
|---|---|---|---|---|---|---|
| Market cap | 6.18T | 58.66B | 200.18B | 146.41B | 155.64B | 26.80B |
| P/E (TTM) | — | — | — | — | — | 28.4 |
| Forward P/E | — | — | — | — | — | 54.2 |
| Price/book | — | — | — | — | — | 2.7 |
| Dividend yield | 0.77% | 3.10% | 2.76% | 3.97% | — | 0.59% |
| 1-year change | −32.88% | −9.73% | −4.90% | −14.43% | −56.76% | −7.77% |
| Today | +5.63% | +0.40% | −0.28% | −1.19% | −3.30% | +5.24% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 20 min.
Latest news
All 000100.KS news ›Yuhan, Boehringer Ingelheim expand parternship for broader healthcare collaboration
Published : Oct. 30, 2026 - 12:49:13 Yuhan and Boehringer Ingelheim are expanding their 16-year partnership beyond pharmaceutical sales into broader healthcare innovation and the development of a sustainable healthcare ecosystem in Korea.…
Peptron ends Yuhan diabetes tech deal, keeps PT302 rights in South Korea
Peptron(087010) and Yuhan(000100) terminated a technology transfer contract for a diabetes treatment worth up to 4 billion won that they signed about 15 years ago. Unlike the original contract value, Peptron actually received only the 1…
Yuhan-Kimberly Plants Endangered Korean Fir Forest at Baekdudaegan Arboretum
Seed Collection and Conservation Under Way Since 2021 500 Ten-Year-Old Saplings From Mount Halla Planted Yuhan-Kimberly is creating a forest of endangered trees in partnership with the Baekdudaegan National Arboretum. The company said on…
Drugmaker Yuhan's historic headquarters wins Korea's top architectural honor
The Willow House / Courtesy of Yuhan Willow House, the historical former headquarters of Korean pharmaceutical pioneer Yuhan Corp., has won the Presidential Award — the grand prize at this year’s Korea Space Culture Awards, the Ministry of…
Yuhan's Lazcluze combination therapy tops $320 million in quarterly sales for first time
1:04 p.m. Oct 14, 2026 The quarterly revenue from the combined therapy of Yuhans' new non-small cell lung cancer drug Lazcluze, marketed as Leclaza in Korea, surpassed $300 million (400 billion won) for the firs
More from 1 other outlet
Yuhan-Kimberly Brings Fan-Requested Kleenex Edition to Emart24
Product developed after viewers asked for it Name blends the Korean word for scrubbing clean with a leopard cat character Yuhan-Kimberly said on the 13th that its Kleenex Facial Tissue Sseukssak Edition has gone on sale exclusively at…
Yuhan accelerates global Leclaza growth as indications widen and reimbursement lags
Rising global uptake hinges on faster reimbursement as costly Leclaza–Rybrevant combo broadens use from surgery prep to post-resistance care Johnson & Johnson (J&J), which is responsible for global development and commercialization, has…
Yuhan Heads to CPHI Milan to Expand Global CDMO Orders
Seoul Economic Daily Yuhan (000100) will set up its own booth at CPHI Milan 2026, the world's largest pharmaceutical and biotech trade show, as it moves to expand its contract development and manufacturing organization (CDMO) business…
Yuhan targets global deals at CPHI to expand Korea’s pharma footprint
Yuhan targets global growth at CPHI Milan, showcasing R&D and CDMO strength - CHOSUNBIZ Chosunbiz Yuhan targets global deals at CPHI to expand Korea's pharma footprint Yuhan(000100) said on Oct. 6 that it will attend the 2026 world…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- biz.chosun.com4
- en.sedaily.com2
- finance.biggo.com2
- mt.co.kr1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 9 articles, not a forecast.